Molecular biology of breast cancer metastasis: Clinical implications of experimental studies on metastatic inefficiency by Chambers, Ann F et al.
Review
Molecular biology of breast cancer metastasis
Clinical implications of experimental studies on metastatic
inefficiency
Ann F Chambers, George N Naumov, Sharon A Vantyghem and Alan B Tuck*
London Regional Cancer Centre and *London Health Sciences Centre, London, Ontario, Canada
Abstract
Recent technological advances have led to an increasing ability to detect isolated tumour
cells and groups of tumour cells in patients’ blood, lymph nodes or bone marrow. However,
the clinical significance of these cells is unclear. Should they be considered as evidence of
metastasis, necessitating aggressive treatment, or are they in some cases unrelated to
clinical outcome? Quantitative experimental studies on the basic biology of metastatic
inefficiency are providing clues that may help in understanding the significance of these
cells. This understanding will be of use in guiding clinical studies to assess the significance
of isolated tumour cells and micrometastases in cancer patients.
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Introduction
Breast cancer is the leading cause of death from
cancer in women, with an estimated 300000 deaths
worldwide attributed to breast cancer in the year 1990
[1,2]. The vast majority of these deaths are due to
metastasis. Women whose breast cancer is detected
and treated prior to metastatic spread of cancer cells
from the primary site have a higher probability of being
cured of their disease, and early detection is thus of
major importance. When breast cancer is detected
after it is known, or suspected, to have metastasized,
treatment decisions are more complex and prognosis is
less favourable.
Metastatic spread has traditionally been assessed by his-
tological examination of lymph nodes for the presence of
metastatic lesions. However, recent technical improve-
ments in the ability to detect cancer cells at distant sites,
in blood, bone, sentinel lymph nodes and other tissues,
and either as isolated cancer cells or as small foci of cells,
have made treatment decisions even more complex. There
are conflicting reports as to the clinical significance of
such isolated cancer cells and small foci [3•]. Should they
be considered as metastases, with the potential to grow
to clinically relevant size, or are they in some cases unre-
lated to clinical outcome? Should the presence of any
cancer cells at sites distant from a primary tumour behttp://breast-cancer-research.com/content/2/6/400
considered as evidence of metastasis, and the patient
thus treated aggressively? This ability to detect smaller
micrometastases, and smaller numbers of isolated tumour
cells, has indeed called into question the definition of
‘metastasis’ [4••]. The ability and likelihood of such cells to
grow to form clinically relevant metastases must be clari-
fied before the ability to detect them can be used clinically
in an appropriate manner.
One solution to this dilemma is to conduct clinical trials to
determine the significance of cancer cells detected at sites
distant from the primary tumour and their ability to predict
the course of disease. Such studies clearly are necessary,
but long-term follow-up periods will be required to validate
the findings. Furthermore, the answers will probably vary
with the type of tumour, features of the primary tumour
(grade, etc) and various markers that are expressed by
cells both in the primary tumour and at the distant sites.
Another complementary approach comes from a growing
understanding of the basic biology of the metastatic
process. Cancer metastasis is known to be an inherently
inefficient process, from several lines of evidence, both
clinical and experimental [5]. Clinically, large numbers of
circulating cancer cells can be detected in blood of
cancer patients, with very small numbers of metastases
resulting [6,7]. Similarly, in experimental studies, large
numbers of cancer cells can be present in the circulation,
either from implanted primary tumours or cancer cells
injected into the circulation, and again relatively few
metastases may result [8–10]. We and our colleagues
have been using experimental in vivo videomicroscopy
(IVVM) procedures in order to understand the biological
and molecular mechanisms of metastasis (for review
[11,12•,13,14,15•]). We have also developed quantitative
procedures to measure formally the efficiency of specific
steps in the metastatic process [16,17]. Recent work by
others, which is discussed below, adds important informa-
tion from independent, complementary experimental
approaches. Together these studies are beginning to
allow clarification of which steps in the process contribute
significantly to metastatic inefficiency, and some of the
molecular mechanisms responsible. These studies can
provide a conceptual framework for understanding the
clinical significance of cancer cells detected at various
points along the metastatic cascade. This understanding
will also aid in guiding clinical studies to assess the signifi-
cance of isolated tumour cells and micrometastases in
specific cancers.
In the present review, we describe some of the experimen-
tal in vivo procedures that we have used to clarify mecha-
nisms of the metastatic process and to determine the
efficiency of specific steps, and we summarize findings
from these studies. We describe some recent findings
from other investigators, which also shed light on metastatic
inefficiency and variability. We conclude that some steps
in metastasis appear to be quite inefficient, and the ability
to accomplish these steps seems to vary markedly
between cancer cells of high versus low metastatic ability,
as well as between different organs. In contrast, other
steps appear to be efficiently carried out, with little depen-
dence on the ultimate metastatic ability of the cells. The
clinical implications of these experimental findings are
considered. We propose that these conclusions may help
in addressing the current clinical dilemma of interpreting
the significance of isolated cancer cells and micrometas-
tases in patients, and that they suggest appropriate direc-
tions for future research.
Experimental approaches for studying
sequential steps of metastasis
In vivo videomicroscopy
IVVM procedures permit direct observations of sequential
steps of the process of metastasis, as they occur in real
time in living experimental animals. The equipment
required is relatively straightforward, and includes an
inverted microscope with epifluorescence illumination
capability, connected to a video camera, computer and a
video recorder. Oblique transillumination, provided by a
fibre-optic light source, permits clear visualization of
tissues and the microcirculation. We have used this
approach to observe steps in metastasis after injection of
cells into the circulation (‘experimental metastasis’) for a
variety of cancer cell types in several target organs. We
are extending these studies to observations of steps in
metastasis of cells implanted orthotopically to form
primary tumours (‘spontaneous metastasis’). IVVM
methodologies that we have developed and used have
been described in detail previously (for review [11,12•,13,
14,15•]), so only a brief summary is provided here.
Fig. 1 presents an example of the sort of in vivo images
that can be obtained, in the context of ongoing experi-
ments in our laboratory on spontaneous metastasis of
breast cancer cells (Vantyghem et al, unpublished data).
Fig. 1a shows the vascular and lymphatic circulatory struc-
ture within a normal (nontumour-bearing) murine mammary
fat pad; in the video recording from which this view was
derived, lymphatic and blood flow patterns within the
mammary gland can readily be observed. Fig. 1b shows
the structure of a lymph node draining this mammary fat
pad; in the original video recording, the three-dimensional
structure can be visualized by focusing up and down
through the lymph node.
Visualization of cancer cells by IVVM requires that the
injected cells be labelled with a marker to help distinguish
them from the surrounding normal tissue. We have used
three types of cell markers: naturally expressed endoge-
nous products (such as melanin; eg [16,17]), exogenously
added cytoplasmic labels (Calcein-AM [Molecular Probes,Breast Cancer Research    Vol 2 No 6 Chambers et al
Eugene, Oregon, USA] or virus-sized fluorescent ‘nanos-
pheres’ [18,19]), and transfected endogenous markers
(green fluorescent protein [20]). Fluorescently labelled
cells can be injected via a blood vessel that feeds the
organ of interest. For example, in order to study metastatic
growth in liver, cells can be injected into a mesenteric vein
(we have observed that injection into the spleen, as used
previously by others to target liver, also results in a large
influx of leucocytes into the liver, so we have avoided that
route). Other routes can be used to target cells for obser-
vations in lung or muscle, etc. At various time points later,
animals are surgically opened in order to partially expose
the organ with its blood flow intact, and the anaesthetized
animal is positioned on the inverted microscope with the
exposed organ gently pressed against a coverglass above
the objective lenses. This positioning keeps the lower
surface of the organ stationary and in focus, in spite of
motion in the rest of the organ due to respiration. Transillu-
mination is used to identify stromal cells, red blood cells,
leucocytes, and the anatomical structures of the organ
and its microcirculation. Epifluorescence illumination
permits positive identification of cancer cells within a field
of view. Real-time images are captured using a video
camera with extended red sensitivity, and are video
recorded. This approach has permitted detailed and direct
observation of sequential steps in ‘experimental’ metasta-
sis as they occur in vivo.
Other laboratories have used a variety of in vivo recording
procedures and have obtained results that complement
those that we have obtained. For example, Farina et al
[21] described a confocal in vivo imaging approach, and
have used this to make observations on cell motility in
orthotopically implanted mammary tumours in rat. Sckell et
al [22] used in vivo video observation techniques, notably
for clarifying vascular patterns in tumours. Scherbarth and
Orr [23] used an experimental set up similar to that
described above, and have provided information on the
cytokine-dependence of the position of cell arrest in liver.
Quantification of metastatic inefficiency
In order to be able to quantify metastatic inefficiency and
the loss of cancer cells at specific steps in the metastatic
process formally, we developed an ‘accounting’ technique
that is able to measure survival of cancer cells at various
times after their injection into the circulation of experimen-
tal animals [16,17] (for review [12•,15•]). For this purpose
it is necessary to express the number of cells observed
(per sample volume of tissue) relative to the number of
cells originally delivered to that volume. Inert plastic fluo-
rescent microspheres (10mm diameter) are included in the
cell suspension at a known cell:microsphere ratio (for
example, 1 microsphere per 10 cells). After injection, the
microspheres are trapped by size restriction in the micro-
circulation, where they permanently remain. Thus, at any
time after injection, the total number of microspheres that
are present in an observed tissue volume provides a refer-
ence to the number of cancer cells that originally arrived in
the same region. The percentage of cells surviving to that
point in time can then be calculated by following equation.
Figure 1
IVVM images of normal (nontumour-bearing) murine mammary fat pad and lymph node. (a) Mammary fat pad, viewed with IVVM, showing three-
dimensional structure of vessels and tissue. Direction of lymphatic flow is indicated by the arrow located within the lymphatic vessel (®). Flow
within the adjacent blood vessels (Ø) was in the same direction. Another vessel (indicated with open arrowhead), was out of the plane of focus and
could be resolved by focusing up and down through the tissue. 200×. (b) The inguinal lymph node (LN) found within mammary fat pad #4 where a
large internal mammary vessel (*) branches. 40×.http://breast-cancer-research.com/content/2/6/400
Cell:microsphere ratio in the liver after injection
×100%
Cell:microsphere ratio in the syringe before injection 
The same principle can be used to calculate the survival of
cells even after they have begun to grow to form metas-
tases, because metastases have been shown to be clonal
in origin [24,25]. This technique may be used in conjunc-
tion with IVVM for observations of superficial regions of
organs, or after fixation the tissue may be sampled
throughout its entirety using 30–50mm thick sections (eg
[17]). Fig. 2 presents a diagram of this ‘accounting’ proce-
dure and provides an example of how metastatic efficiency
is calculated, as percentage cell survival at various times
after injection, relative to the number of cells delivered to a
tissue volume.
In combination, IVVM and cell ‘accounting’ techniques
provide a high-resolution means of quantifying metastatic
efficiency at sequential steps in the metastatic process.
The proportion of injected cells that survive in the circula-
tion, arrest in an organ, extravasate and survive in the
tissue (as dormant solitary cells, early micrometastases, or
progressively growing metastases) can be formally quanti-
fied, and the behaviour of cells at these steps in the
metastatic process can be observed at high resolution.
Metastatic inefficiency: conclusions from
recent experimental studies
Our results using the IVVM and cell ‘accounting’ proce-
dures described above, with a variety of cancer cell types
injected into the circulation in order to target various
organs in experimental mice (as well as chicken embryos),
have produced a remarkably consistent picture of the
metastatic process and steps that appear to contribute to
overall metastatic inefficiency. The experimental findings
are not reviewed in detail here, because these are summa-
rized in several recent reviews [11,12•,13,14,15•]. Instead,
we outline our conclusions from these studies, bearing in
mind that these are generalizations based on specific
experiments, and that exceptions to these conclusions
may well exist.
We have found that cells survive in the circulation with high
efficiency (often greater than 80% of the original cell inocu-
lum). This survival can be equally high in organs with high
and low circulatory pressure (eg murine muscle, liver, lung;
chick embryo chorioallantoic membrane). Similarly, survival
in the circulation does not appear to depend on the degree
of malignancy of the cells, with cells of high and low malig-
nancy surviving equally well. Cells arrest initially in the
target organ on the basis of size constraints, with cancer
cells (which are often much larger than red or white blood
cells) travelling in the circulation until they are arrested in
microcirculatory vessels. This process of arrest is also
highly efficient, with very high cell survival, and appears to
be independent of the malignant potential of the cells.
We also have found that extravasation, the escape of cells
from the circulation, is highly efficient, with greater than
80% of cells successfully completing this process. This
finding was independent of cancer cell type or degree of
malignancy of the cells. Indeed, we found that metastatic,
ras-transformed NIH3T3 fibroblasts, control NIH3T3 cells,
and even primary culture normal mouse embryo fibroblasts
all extravasated with high efficiency and similar kinetics
[26]. Thus, to this point in the process of ‘experimental’
metastasis (ie from intravenously injected cells [27•]) all
steps appear to be completed with high efficiency, and
independent of the degree of metastatic ability of the cells.
Once cells have completed extravasation, however, they
appear much less efficient and more variable at completing
subsequent steps in the metastatic process. In a detailed
study of metastatic inefficiency of B16F1 murine melanoma
cells injected to target liver [17], we found that more than
80% of injected cells survived in the circulation, arrested in
the microcirculation, and successfully extravasated.
However, only a small subset of extravasated cells began to
grow (approximately 2% of injected cells), and only a subset
of micrometastases that began to grow persisted in their
growth to form large metastases (approximately 0.02% of
injected cells). We are finding similar patterns for other cell
Figure 2
Cell ‘accounting’ procedure for quantifying in vivo cell survival and
metastatic efficiency. Inert plastic fluorescent microspheres
(approximately 10mm) are included in a cell suspension, in a known
cell : microsphere ratio. The suspension is injected intravenously to
target an organ (eg mesenteric vein to target liver). The microspheres
remain indefinitely where they arrest in the microcirculation, providing a
reference marker for the number of cells that originally reached that
volume of tissue. Based on cell:microsphere ratios at later times, the
percentages of surviving cells can be calculated (see example
provided).lines and organs, such as the following: B16F10 cells in
lung [28]; mammary carcinoma cells of high versus low
metastatic ability in liver (Naumov et al, unpublished data);
and ras-transformed and control fibroblasts in liver (Vargh-
ese et al, unpublished data). The details of the percentage
efficiency of postextravasation growth appears to vary for
different cell lines and organs. These variations (rather than
variations in delivery of cells to different organs) seem to be
responsible for much of organ-specific metastasis (for dis-
cussion [14,15•]). However, the generalizations that early
steps (survival in the circulation, arrest in the microcircula-
tion, extravasation) are efficiently completed, while later
steps of initiation and persistence of growth after extravasa-
tion are inefficient and variable depending on the cell line
and organ, seem to be consistent.
In addition, we have repeatedly observed isolated tumour
cells persisting in secondary sites after extravasation,
often for long periods of time. These numbers can be quite
high, and may not be related to the metastatic ability of the
cell line. For B16F1 cells in liver, we found that 36% of
injected cells persisted in a dormant state (ie negative for
either proliferation/Ki67 or apoptosis/TUNEL) in the organ
for the full 2-week period of observation, whereas a
smaller subset of cells grew to form metastases [17]. In
addition, the evidence suggested that cells that initiated
division were more vulnerable to loss than cells that
remained dormant. Similar dormant cells have been
observed in murine mammary carcinoma cell lines that
were injected to target them to liver, up to 11 weeks after
cell injection, as detected both in vivo by their retention of
fluorescent nanospheres (which are diluted out by cell divi-
sion) as well as by histology (Naumov et al, unpublished
data). Surprisingly, much larger numbers (approximately
80% of the injected cells) of undivided, dormant cells
were detected in a poorly metastatic cell line (D2.OR)
compared with a highly metastatic one (D2A1). Fig. 3
shows the appearance of such dormant cells, detected by
their fluorescence (Fig. 3a) and histologically (Fig. 3b).
Collectively, the results from several cancer cell lines
suggest that dormant cells may persist in tissues, and may
fail to progress to form metastases.
Recent studies on metastasis-suppressor genes support
the idea that the presence of cancer cells in distant
organs is not necessarily predictive of their ability to grow
to form metastases (for review [29]; Yoshida et al, unpub-
lished data). For both prostate cancer and melanoma
models, metastasis-suppressor genes have been shown
[30•,31•] to result in growth suppression of cells that have
not lost their ability to disseminate to distant organs. The
clear clinical implication of this conclusion, derived
independently from the quantitative studies on metastatic
inefficiency described above, and studies on metastasis-
suppressor genes, is that detection of cancer cells in sec-
ondary organs may not be predictive of their ability to
grow to form metastases.
Our studies to date have not examined the earliest step in
the process: intravasation of cells from a primary tumour.
However, Farina et al [21] have used green fluorescent
protein-labelled rat mammary carcinoma cells implanted
orthotopically into rat mammary fat pads. Using this model,
this group recently has compared highly with poorly
metastatic cell lines for their ability to intravasate [32].
They found that the intravasation process appeared to be
Breast Cancer Research    Vol 2 No 6 Chambers et al
Figure 3
In vivo detection of solitary mammary carcinoma cells in murine experimental metastasis model. (a) Solitary murine mammary carcinoma (D2.OR)
cells (®), fluorescently labelled, are present within normal liver tissue 11 weeks after intravenous injection to target the liver. In close proximity to
the cells is a fluorescent ‘accounting’ microsphere (Ø), approximately 10mm in diameter. The image was obtained by IVVM using epifluorescence
plus transillumination. (b) Similar solitary mammary carcinoma cell (®; ~10–15mm in diameter) in murine liver, 11 weeks after injection, detected
by haematoxylin and eosin staining.inefficient. Furthermore, they found that the highly malig-
nant cells intravasated, whereas the poorly metastatic
ones failed to do so, as detected by cells in blood. Thus,
the intravasation step may be inefficient and related to the
malignancy of cells in the primary tumour. Interestingly,
however, a recent study [33] presented evidence that
cells that have been shed from a primary tumour, in an
experimental colon cancer model, may have reduced
malignancy relative to the parental cell line. This suggests
that cells that successfully intravasate from a highly
metastatic tumour cell line may not all have or retain this
phenotype. Thus, detection of cells in the circulation may
indicate a high degree of malignancy of the primary
tumour, although the detected cells may or may not retain
this property, and their presence is not necessarily predic-
tive of risk for metastasis.
Fig. 4 presents a summary of the conclusions described
above, derived from our results as well as those of other
groups. We present this diagram as a point for discussion.
It should be borne in mind that the dogmatic statements
presented are probably over-simplifications, derived from
specific experimental studies, and may not necessarily be
generalizeable. However, patterns emerge from this analy-
sis that we believe will be helpful in guiding future experi-
ments, as well as in interpreting the potential clinical
significance of cancer cells that are identified at various
points in the metastatic cascade.
Clinical implications of experimental studies
on metastatic inefficiency
Metastasis is responsible for most cancer mortalities, and
one might thus suppose that any indication of metastatic
cells would therefore justify aggressive therapy. However,
the prognostic significance of individual tumour cells in
blood, bone marrow, or lymph node has recently been
called into question. Treatment decisions for metastatic
breast cancer have been made more difficult by an
increasingly sensitive ability to detect these cells, coupled
with limited clinical data to assess their significance to
patient prognosis [3•,4••,34,35•,36•]. Immunohistochemi-
cal techniques to detect isolated carcinoma cells or
micrometastases in blood or tissues, using antibodies
against epithelial markers such as cytokeratins (eg
[3•,34,36•,37]) or reverse transcription polymerase chain
http://breast-cancer-research.com/content/2/6/400
Figure 4
Summary of observations regarding efficiency of specific steps in
metastasis, and their dependence on the degree of malignancy of the
cells. Conclusions are based on specific experimental results
presented in the text.
Figure 5
Isolated breast cancer cell and micrometastasis in sentinel lymph node. (a) Individual isolated tumour cell (®) and (b) small micrometastatic group
of tumour cells (®) in the sentinel lymph node of two different breast cancer patients, as detected with anticytokeratin (AE1/AE3) antibodies
(400×). The clinical relevance of (a) versus (b) is at present unclear.Breast Cancer Research    Vol 2 No 6 Chambers et al
reaction assessment for various markers that are thought
to be specific for cancer cells [38–41], have shown that
such cancer cells can be detected in many patients.
However, the clinical significance of these cells remains
controversial and poorly understood [3•,4••,35•,42–44].
Fig. 5 shows an isolated tumour cell and a small group of
tumour cells detected in sentinel lymph nodes of two breast
cancer patients using anticytokeratin antibodies. Do such
cells represent a pool of viable cancer cells that will go on
to form clinically important metastases? Alternanatively, can
such cells be detected which, in some cases, are of no (or
limited) negative consequences to the patient?
The experimental studies summarized herein suggest that
the detection of individual tumour cells and small groups
of tumour cells at distant sites does not, in itself, necessar-
ily predict that metastases will grow in these patients. Evi-
dence has been presented to show that such cells can
readily be detected, in model systems, from nonmetastatic
or poorly metastatic cell lines. As outlined in Fig. 4, there is
a large degree of inefficiency and much variation between
different cell lines in the steps of metastasis that must
occur after the stage of detection of isolated cells and
small micrometastases. Not all isolated cancer cells will go
on to grow, and not all micrometastases that initiate
growth will persist in growth to form clinically relevant
metastases. Markers to determine which of these cells are
associated with subsequent formation of macrometas-
tases must be evaluated, and associations with clinical
outcome in cancer patients must be explored. Without this
information, detection of isolated tumour cells and groups
of such cells in patients’ blood, sentinel lymph nodes or
distant sites will remain an unreliable prognostic indicator.
Conclusion
The experimental studies described above suggest that few
isolated cancer cells detected in secondary sites may begin
to grow, and not all micrometastases that begin growth may
persist to form macrometastases. Significant inefficiency
and variability in the metastatic process occur during the
growth of cancer cells in secondary sites. Based on biologi-
cal considerations, the presence of isolated tumor cells or
cell clusters at distant sites would not, in itself, be expected
to be a reliable predictor of subsequent development of
macrometastases, and markers that are associated with
clinical outcome must be evaluated for these cells.
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